citalopram has been researched along with Cancer of Head in 4 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Of the 125 evaluable patients with stages II through IV HNC but without baseline depression, 60 were randomized to prophylactic antidepressant escitalopram oxalate and 65 to placebo at the time of the initial diagnosis." | 5.27 | Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial. ( Burke, WJ; Lydiatt, WM; Panwar, A; Rieke, K; Sayles, H, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Panwar, A | 1 |
| Rieke, K | 1 |
| Burke, WJ | 4 |
| Sayles, H | 2 |
| Lydiatt, WM | 4 |
| Bessette, D | 1 |
| Schmid, KK | 1 |
| Lazure, KE | 1 |
| Denman, D | 2 |
| McNeilly, DP | 1 |
| Puumula, SE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer[NCT05724849] | Phase 2 | 64 participants (Anticipated) | Interventional | 2023-08-01 | Not yet recruiting | ||
| Prevention of Depression in Patients Being Treated for Head and Neck Cancer[NCT00536172] | Phase 4 | 160 participants (Actual) | Interventional | 2007-12-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants reaching pre-defined threshold on the QIDS-SR-16 of >/=11. The QIDS-SR-16 total score ranges from 0-27. Scores ranging from 0 to 10 correspond with no to mild depression, while scores >/= 11 correspond to moderate to severe depression. (NCT00536172)
Timeframe: Measured pre-treatment and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 28
| Intervention | participants (Number) |
|---|---|
| Escitalopram | 6 |
| Placebo | 16 |
4 trials available for citalopram and Cancer of Head
| Article | Year |
|---|---|
Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Female; Head | 2018 |
Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial.
Topics: Chi-Square Distribution; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Head a | 2013 |
Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial.
Topics: Chi-Square Distribution; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Head a | 2013 |
Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial.
Topics: Chi-Square Distribution; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Head a | 2013 |
Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial.
Topics: Chi-Square Distribution; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Head a | 2013 |
Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Carcinoma, Squamous Cell; | 2009 |
A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Depressive Dis | 2008 |